Search results
FDA approves generic Emflaza oral suspension for Duchenne muscular dystrophy
Medical Xpress· 1 day agoThe U.S. Food and Drug Administration has approved the first generic version of Emflaza...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open
Barrons.com· 5 days agoThe drug company Pfizer said a gene therapy it is testing failed to improve motor function in boys...
Study finds LED therapy and antioxidant drug benefit muscle regeneration in Duchenne muscular ...
Medical Xpress· 4 days agoAs reported in an article published in the journal PLOS ONE, the strategy prevented muscle...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with ...
Morningstar· 6 days ago(NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene ...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 5 days agoSarepta Therapeutics, a Cambridge drugmaker known for its Duchenne muscular dystrophy treatments,...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 5 days agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 5 days agoPfizer has reported that its Phase III CIFFREO clinical trial of investigational mini-dystrophin...
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Morningstar· 5 days agoShares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial. Pfizer Inc. said late Wednesday that ...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 6 days agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 4 days agoPfizer’s PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...